Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The dexamethasone suppression test in borderlines: is it useful?

M Korzekwa1, M Steiner, P Links

  • 1McMaster University, Hamilton, Ontario.

Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie
|February 1, 1991
PubMed
Summary

The Dexamethasone Suppression Test (DST) is not a reliable biological marker for diagnosing major depressive disorder (MDD) in patients with borderline personality disorder (BPD). This study found low sensitivity and specificity, questioning its clinical utility for this population.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Results of endovascular treatment of aneurysms depending on their size, volume and coil packing density.

Neurologia i neurochirurgia polska·2013
Same author

[Reconstruction of mutism. Studies of subjective experiences of former patients with the modified Landfield categories].

Psychiatrische Praxis·2001
Same author

Recognition of premenstrual dysphoric disorder and its treatment.

Lancet (London, England)·2000
Same author

A PET study of brain 5-HT2 receptors and their correlation with platelet 5-HT2 receptors in healthy humans.

Psychopharmacology·2000
Same author

[Self concept and object relations of patients with affective disorders--individual centered diagnosis with the repertory-grid technique].

Psychotherapie, Psychosomatik, medizinische Psychologie·2000
Same author

Phenol sulphotransferase SULT1A1 polymorphism in prostate cancer: lack of association.

Archives of toxicology·2000

Area of Science:

  • Psychiatry
  • Neurobiology
  • Clinical Psychology

Background:

  • The link between borderline personality disorder (BPD) and major depressive disorder (MDD) remains debated.
  • A validated biological marker is needed for diagnosing depression in BPD patients and predicting treatment response.

Purpose of the Study:

  • To evaluate the Dexamethasone Suppression Test (DST) as a biological marker for MDD in patients with BPD.
  • To determine the DST's utility in differentiating BPD patients with and without MDD.

Main Methods:

  • Sixty-seven patients meeting BPD criteria were assessed using the DST.
  • Fifty of these patients also met criteria for MDD; 34 had endogenous depression.

Main Results:

Related Experiment Videos

  • The DST was positive in 23.9% of all BPD patients.
  • DST positivity was 26.0% in BPD patients with MDD and 17.6% in those with endogenous depression.
  • Low sensitivity and specificity of the DST were observed for depression in BPD.

    • Conclusions:

    • The DST is not a useful diagnostic tool for identifying MDD in BPD patients.
    • Findings suggest the DST is unsuitable for differentiating BPD patients with or without MDD.
    • Further research is needed to understand the nature of depression in BPD.